Evidence mapPaperPMID 41923099Full record

ArticleJournal of experimental & clinical cancer research : CR2026

Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3

Peng Zhou, Huiheng Qu, Yu Tang, Kaihang Shi, Zequn Zhuang, Chen Qiu, Yupeng Zhao, Youwei Han, Zhihui Yang, Yuyan Ding and 5 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Peng Zhou *Department of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China.
Huiheng Qu *Department of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China.
Yu Tang *Department of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China.
Kaihang Shi *Department of Hepatobiliary Surgery, The Affiliated Yixing Hospital of Jiangsu University, Wuxi, Jiangsu, China.
Zequn ZhuangDepartment of Hepatobiliary Surgery, Jinjiang Municipal Hospital (Shanghai Sixth People's Hospital Fujian), Quanzhou, Fujian, China.
Chen QiuDepartment of General Surgery, The Affiliated Wuxi No.2 People's Hospital, Wuxi Medical Center of Nanjing Medical University, Wuxi, Jiangsu, China.
Yupeng ZhaoDepartment of General Surgery, Zhongda Hospital Southeast University, Nanjing, Jiangsu, China.
Youwei HanDepartment of General Surgery, The Affiliated Wuxi No.2 People's Hospital, Wuxi Medical Center of Nanjing Medical University, Wuxi, Jiangsu, China.
Zhihui YangDepartment of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China.
Yuyan DingDepartment of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China.
Tianlu JiangDepartment of Breast Surgery/General Surgery, The Affiliated Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Wuxi, Jiangsu, China.
Shuai LiangDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Kaiyuan DengDepartment of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China. leodky1988@126.com.
Yigang ChenDepartment of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China. 9862023226@jiangnan.edu.cn.
Jiazeng XiaDepartment of General Surgery / Research Institute of General Surgery, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, China. xiajzwuxi@163.com.

Funding

National Natural Science Foundation of China Youth Fund 82503303Wuxi Commission of Health Q202514Wuxi Medical Key Discipline Construction Project, Medical Development Discipline FZXK2021009Wuxi Taihu Lake Talent Plan, Team in Medical and Health Profession THRC0003
6 · The paper itself

Abstract

backgroundThe incidence and mortality of gastric cancer (GC) are still in the forefront worldwide. Up to now, the population benefiting from immunotherapy is still very limited. Tumor associated macrophages (TAM) play an important role in immune response and immune microenvironment remodeling. This study aimed to clarify the altered TAM subsets in GC microenvironment and elucidate the internal molecular mechanism.

methodsSample collection and Cytometry by Time-of-Flight (CyTOF) were used to identify TAM subpopulations with differential infiltration in the GC microenvironment, followed by multiplex immunofluorescence and flow cytometry to validate the immunosuppressive function. Exosomes were isolated and characterized by transmission electron microscopy, nanoparticle tracking analysis and western blot for subsequent high-throughput RNA sequencing. The key regulatory role of LAG3+ TAMs in the progression of gastric cancer was explored by Chromatin Immunoprecipitation, dual luciferase reporter, cytokine array and subcutaneous xenograft models.

resultsThe infiltration of LAG3+ TAMs was elevated in GC and correlated with poorer prognosis. LAG3+ TAMs significantly suppressed the effector function and cytotoxic activity of CD8+ T cells. Mechanistically, GC cells-derived exosomes delivered miR-151a-5p to macrophages, inducing LAG3 expression via DUSP8/MAPK-dependent activation of ELK1 transcription. Reciprocally, LAG3+ TAMs released CXCL8, which bound CXCR2 on GC cells, amplifying exosomal miR-151a-5p secretion and reinforcing the immunosuppressive loop.

conclusionsLAG3⁺ TAMs are expanded in GC through a tumor-macrophage feedback circuit driven by exosomal miR-151a-5p, resulting in CD8⁺ T-cell dysfunction and immune resistance. Targeting this axis may enhance GC immunotherapy efficacy.

Indexed as

Antigens, CDExosomesMicroRNAsStomach NeoplasmsTumor-Associated MacrophagesTumor MicroenvironmentAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansLymphocyte Activation Gene 3 ProteinMacrophagesMiceAntigens, CDLymphocyte Activation Gene 3 ProteinMicroRNAsExosomeGastric cancerImmunotherapyLymphocyte-activation gene 3Tumor-associated macrophage

Identifiers

PMID41923099
PMCPMC13170018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.